Ceapro Inc V.CZO

RE:RE:RE:RE:RE:RE:RE:RE:Price action

[Everestbaker]

" While the beta glucan pill suffered an unfortunate fate that's life and its pursuit led to PGX. CZO could go back to beta glucan in the future. It is not over for beta glucan; but CZO has other immediate priorities."

No ifs and buts Proph. This is why Giles is paid the big bucks. The communication and execution around this failed trial was abysmal - and no wonder it failed. You harp about "preclinical data", "transformational", etc. but us longs have heard and read this before multiple times (Here's the BG study link again). Fool me once, shame of you. Fool me twice,... So like Fossil said, the AGM results will reflect what shareholders think. No amount of same spam repeated ad nauseum will help.

FAILED 2018-2020 BG study announcement:

“The commencement of this study represents a noteworthy milestone in the development of our beta glucan program and could be the most significant transformational step we have taken to date in executing on our strategy to transition Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product in a multi-billion dollar and growing market. On the technical side, we are pleased with the final formulation of beta glucan powder, which has been produced in house using our disruptive PGX technology and additionally with the final tablet developed with Montreal-based specialty pharmaceutical companies, Corealis and Halo Pharma, who respectively completed the pharmaceutical development and the production of clinical lots for the trial. We are extremely grateful to be working with the expert team led by Dr. Tardif at MHI and MHICC, who shares a synergistic goal in Ceapro’s contemplated sector of activities in inflammation-based diseases, metabolic syndrome and other lifestyle diseases,” added Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.